Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
  • In 2017, two projects were funded by Shanghai Science & Technology Commission, one project received funding from China's Ministry of Science and Technology. 2017-12-30 16:50
  • FDZJ successfully achieved IPMS certification. 2017-10-18 15:06
  • The Permission for Clinical Trial for Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection was issued 2017-02-01 10:35
  • The official market launch of FuMeiDa from FDZJ brought new hope to patients with port wine stains 2016-12-05 14:20
  • The success of obtaining drug approval of Hemoporfin (FuMeiDa) as a class 1 new drug 2016-10-20 14:00
  • Air conditioning system design of small capacity injection workshop won the award of CIFA-ISPE 2016-04-19 10:10
  • ALA® has been successfully selected the "National New Products Program" and awarded as the "National Strategic Innovative Product" 2015-04-03 12:50
  • 2014 Enviroment Report 2015-04-02 16:50
  • 2013 Enviroment Report 2014-03-31 16:27
  • Fudan-Zhangjiang Successful Listing on the Main Board of HKEx 2013-12-18 15:52
  • The Success of the Initiation of Marketing of FMD® (Hemoporfin) 2013-12-16 14:04
  • Honor rewarded again for FDZJ 2013-08-27 12:05
  • The company’s product “Aminolevulinic Acid Hydrochloride (ALA ®)” has been granted award of “the Top 100 Shanghai High-tech Achievement Transformation Project in 2011” 2012-07-31 11:41
  • A strategic cooperation agreement on innovative drug research and development (r&d) was signed between Shanghai Medical Group and Shanghai Fudan-Zhangjiang 2011-02-24 15:52
  • Mr. Sheng Xiaoming, the vice mayor visited FDZJ as an inspection and investigation 2009-02-27
  • Member of the Standing Committee of the CPC Shanghai Committee, secretary of the CPC Pudong New District Committee Xu Lin and other government officers visited our company to investigate the status of the research and development of innovative drugs 2008-09-13
  • FDZJ registered and constructed FDZJ’s Taizhou Pharmaceutical Limited Company with the name of "Taizhou Medicine", a subsidiary located in Taizhou City, Jiangsu Province 2007-3-27
  • The Permission for Clinical Trial for Nifeviroc, a New Drug (Class 1.1), was Issued. 2007-3-22
  • Beixi®, Down’s Screening System, obtains the support of “National Torch Plan” 2007-2-22
  • Licenses for Aminolevulinic acid (ALA) Issued by SFDA in Feb. 2007 and Sales Started in May, 2007 2007-2-14
  • Page: 1/2  Per Page20  Total 32  No.: [1][2]

    Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
    (沪)-非经营性-2015-0015    沪ICP备10027510号-1